Want to see IN:FDC full AI Analyst Report?
FDC Ltd. (FDC) AI Stock Analysis
FDC Ltd.
(NSE:FDC)
FDC Ltd. earns a moderate overall score of 68, primarily driven by its fortress-like balance sheet and steady revenue generation. The company's fair valuation further supports its fundamental strength. However, the score is notably constrained by strong bearish technical trends, with the stock trading well below its major moving averages, though currently flashing oversold signals. Earnings call and corporate events components were excluded from this calculation due to missing data.
FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 61.38B
- Dividend Yield
- 1.32%
- Average Volume (3M)
- 13.23K
- Price to Earnings (P/E)
- 19.6
- Beta (1Y)
- 0.85
- Revenue Growth
- 10.20%
- EPS Growth
- 38.95%
- Country
- India
- Employees
- 7,076
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
FDC Ltd. Business Overview & Revenue Model
Company Description
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectiv...
How the Company Makes Money
FDC makes money primarily by selling pharmaceutical and healthcare products. Revenue is generated from (1) sales of prescription medicines supplied to healthcare providers, hospitals, and pharmacies, and (2) sales of other healthcare products sold th...
FDC Ltd. Financial Statement Overview
Summary
FDC Ltd. demonstrates a highly stable financial position anchored by steady revenue expansion and an exceptionally strong, nearly debt-free balance sheet. While profit margins remain healthy, intermittent volatility in net earnings and a recent decline in free cash flow slightly weigh on the score.
Income Statement
80PositiveBalance Sheet
96Very PositiveCash Flow
72Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.89B | 21.71B | 21.08B | 19.35B | 17.84B | 15.26B |
| Gross Profit | 9.74B | 9.18B | 8.36B | 6.51B | 11.28B | 9.78B |
| EBITDA | 3.79B | 4.39B | 4.15B | 4.40B | 3.01B | 3.30B |
| Net Income | 3.13B | 2.81B | 2.67B | 3.05B | 1.94B | 2.16B |
Balance Sheet | ||||||
| Total Assets | 31.76B | 29.19B | 27.14B | 24.68B | 23.43B | 22.70B |
| Cash, Cash Equivalents and Short-Term Investments | 6.22B | 5.23B | 5.37B | 4.75B | 4.84B | 5.39B |
| Total Debt | 128.20M | 154.65M | 211.68M | 205.19M | 283.20M | 322.04M |
| Total Liabilities | 5.07B | 4.34B | 4.33B | 3.71B | 3.62B | 3.14B |
| Stockholders Equity | 26.69B | 24.85B | 22.81B | 20.97B | 19.82B | 19.57B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 622.92M | 2.67B | 1.27B | 418.21M | 291.08M |
| Operating Cash Flow | 0 | 2.49B | 3.64B | 2.21B | 1.55B | 1.62B |
| Investing Cash Flow | 0 | -1.59B | -2.47B | -170.83M | 111.35M | -1.45B |
| Financing Cash Flow | 0 | -925.39M | -913.47M | -2.02B | -1.80B | -98.37M |
FDC Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Positive. The current price of 381.10 is above the 20-day moving average (MA) of 345.69, above the 50-day MA of 345.96, and above the 200-day MA of 370.66, indicating a bullish trend. The MACD of 5.93 indicates Negative momentum. The RSI at 66.77 is Neutral, neither overbought nor oversold. The STOCH value of 84.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FDC.
FDC Ltd. Peers Comparison
Overall Rating
IN:STAR74Outperform
IN:BLISSGVS69Neutral
IN:FDC68Neutral
IN:ORCHPHARMA54Neutral
IN:UNICHEMLAB51Neutral
IN:INDOCO50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | INR 98.55B | 15.97 | ― | 0.47% | 11.28% | 55.18% | |
| 69Neutral | INR 68.94B | 50.66 | ― | 0.23% | 20.59% | 27.16% | |
| 68Neutral | INR 61.32B | 19.59 | ― | 1.32% | 10.20% | 38.95% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 49.89B | 489.15 | ― | ― | 10.83% | -89.83% | |
| 51Neutral | INR 34.04B | 11.17 | ― | ― | 9.43% | 132.94% | |
| 50Neutral | INR 19.23B | 61.26 | ― | 0.10% | 10.75% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:FDC | FDC Ltd. | 376.65 | -78.95 | -17.33% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 648.40 | 494.04 | 320.05% | |
| IN:INDOCO | Indoco Remedies Limited | 208.35 | -64.66 | -23.68% | |
| IN:ORCHPHARMA | Orchid Pharma Limited | 833.05 | 64.40 | 8.38% | |
| IN:STAR | Strides Pharma Science Ltd | 1069.15 | 89.49 | 9.13% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 483.45 | 9.00 | 1.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026